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Abstract 
Background : Atherosclerosis and non-alcoholic fatty liver disease (NAFLD) are complex 
pathologies characterized by lipid accumulation, chronic inflammation and extensive tissue 
remodelling. Microparticles (MPs), small membrane vesicles produced by activated and 
apoptotic cells, might not only be biomarkers, but also functional actors in these pathologies. 
The apoE2-KI mouse is a model of atherosclerosis and NAFLD. Activation of the nuclear 
receptor PPAR decreases atherosclerosis and components of non-alcoholic steatohepatitis 
(NASH) in the apoE2-KI mouse. 
Objectives : 1) To determine whether MPs are present in atherosclerotic lesions, liver and 
plasma during atherosclerosis and NASH progression in apoE2-KI mice, and 2) to study 
whether PPAR activation modulates MP concentrations. 
Methods : ApoE2-KI mice were fed a Western diet to induce atherosclerosis and NASH. MPs 
were isolated from atherosclerotic lesions, liver and blood and quantified by flow cytometry. 
Results : An increase of MPs was observed in the atherosclerotic lesions and in the liver of 
apoE2-KI mice upon Western diet feeding. PPAR activation with fenofibrate decreased MP 
levels in the atherosclerotic lesions in a PPAR-dependent manner, but did not influence MP 
concentrations in the liver. 
Conclusion : Here we report that MPs are present in atherosclerotic lesions and in the liver of 
apoE2-KI mice. Their concentration increased during atherosclerosis and NASH development. 
PPAR activation differentially modulates MP levels in a tissue-specific manner. 
 
Keywords : microparticles, atherosclerosis, fatty liver disease, pharmacology, murine model 
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Introduction 
The prevalence of metabolic syndrome associated with visceral obesity is in constant 
progression world-wide [1, 2], resulting in a high risk of developing complications such as 
diabetes and cardiovascular diseases. These pathologies are pathophysiologically related to 
atherosclerosis and non-alcoholic fatty liver disease (NAFLD), including non-alcoholic 
steatohepatitis (NASH), which display common features such as lipid accumulation and 
inflammation [3, 4]. They develop silently over several years, and are the most common 
causes of cardiovascular and chronic liver diseases. Consequently, early diagnosis of 
atherosclerosis and NASH is crucial to allow early intervention and prevent disease 
progression. Therefore, the discovery of biomarkers is an important approach for the 
diagnosis and prognosis of these diseases. 
Atherosclerosis and NASH progression are both accompanied by inflammation 
development which involves several actors including different chemokines (monocyte 
chemoattractant protein 1, MCP-1), cytokines (tumor necrosis factor, TNF) and 
metalloproteinases (MMP) [5-8]. Tissue remodelling and inflammation, occurring during 
atherosclerosis or NAFLD, may induce microparticle (MP) formation. MPs are small vesicles 
(0.1-1µm) released from cells undergoing apoptosis or under stress conditions such as 
inflammation. MPs expose phosphatidylserine in the outer leaflet of their membrane, allowing 
their quantification by flow cytometry after staining with annexin V coupled to a fluorophore 
[9]. MPs are present at relatively low concentrations in the circulation of healthy individuals. 
Numerous clinical studies have reported increased plasma MP levels associated with 
cardiovascular risk factors (hypertension, smoking, obesity and type 2 diabetes) and 
cardiovascular diseases [10-15]. Moreover, MPs are also present in human atherosclerotic 
lesions [16]. Concerning liver diseases, an increase of plasma MPs has been reported in 
patients with hepatitis C [17] and hepatocellular carcinoma [18], but it is unknown whether 
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liver MPs are detectable in patients with NASH. MPs display several functional properties 
that can influence atherosclerosis and NASH development, such as induction of endothelial 
dysfunction, angiogenesis modulation, inflammation exacerbation and thrombus formation 
[19-22]. Furthermore, several drugs used in the treatment of cardiometabolic diseases, such as 
statins and glitazones, reduce plasma MP concentrations [23, 24]. Thus, MPs might be 
considered as disease biomarkers, and may also be useful to predict drug efficacy in 
preclinical and early clinical development. However, experimental evidence in preclinical 
models on the role of MPs in the pathological processes in vivo is still lacking. Such 
experiments are necessary to further validate MPs as potential disease biomarkers. 
Peroxisome proliferator-activated receptor alpha (PPAR) is a nuclear receptor, 
activated by fatty acids and synthetic ligands such as the hypolipidemic fibrates, which 
regulates the expression of genes implicated in lipid homeostasis and inflammation [25]. 
PPAR agonists inhibit atherosclerosis lesion development in preclinical models[26-28], and 
are of particular interest for the treatment of cardiometabolic diseases, especially in patients 
exhibiting high triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C) levels 
[29, 30]. By contrast, the effects of fibrates on NASH in humans have not been thoroughly 
studied. 
The apolipoprotein E2 knock-in (apoE2-KI) mouse is an experimental model of 
atherosclerosis and NASH [26, 31]. These mice develop spontaneously dyslipidaemia and 
atherosclerotic lesions in the aortic sinus, essentially characterized by foam cell accumulation. 
Treatment with the PPAR activator fenofibrate improves dyslipidaemia and reduces 
atherosclerosis development [26]. Moreover, short-time Western diet feeding is sufficient to 
induce hepatic steatosis and inflammation, effects which can be prevented by fenofibrate 
treatment [31]. 
 5 
The aim of the present study was to determine in apoE2-KI mice whether 1) liver and 
aortic MPs can be detected as markers of disease progression, 2) plasma MPs are diagnosis 
markers of pathology, and 3) to analyse whether MP concentrations can be pharmacologically 
modulated by PPAR activation. Our results show an increase of MP concentrations in 
atherosclerotic lesions and liver of apoE2-KI mice upon Western diet feeding. Fenofibrate 
treatment decreased MP levels in the atherosclerotic lesions in a PPAR-dependent manner, 
but did not influence NASH-associated MP concentrations. 
 
Methods 
 
Animals and diets 
 Homozygous human apoE2-KI mice, which express human apoE2 in the mouse apoE 
locus, were used in this study [32]. For some protocols, homozygous PPAR-deficient mice 
on the C57BL/6 background [33] were crossed with apoE2-KI mice, to generate apoE2-KI 
mice deficient for PPARand their littermates expressing PPAR. 
 Twelve-week old female mice were fed a chow diet or a Western diet (21% fat and 
0.2% cholesterol) (Safe, France) supplemented or not with fenofibrate (0.04% for 10 weeks or 
0.2% for 2 weeks). For NASH studies, the Western diet was supplemented or not with 
fenofibrate 0.2% for 10 days. Doses and treatment durations were chosen according to their 
inhibiting effects on atherosclerotic lesion and NASH development, respectively [26, 31]. All 
experiments were performed with 8 animals per group. 
Blood was obtained after a 4-hour fasting period (9 AM to 13 PM) by retroorbital 
puncture under isoflurane-induced anesthesia, and was collected either on EDTA-coated tubes 
for plasma lipid measurements or in tubes containing trisodium citrate 3.2% at 1 : 10 vol of 
blood for MP quantification.  
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Mice were maintained under a 12 hour light/dark cycle and had free access to food and 
water. All animal experiments were performed with the approval of the Pasteur Institute 
review board, Lille, France. 
 
Biochemical analysis 
 Plasma levels of total cholesterol (TC), TGs and HDL-C were measured using 
commercially available kits (BioMérieux, France). Non-HDL-cholesterol (N-HDL-C) was 
calculated by subtraction of HDL-C from TC.  
 
MP isolation from tissues 
 Fresh tissues (the aortic sinus-containing part of the heart or the liver) were weighed, 
rinsed in PBS solution and homogenized in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Gibco, 10 µL/mg tissue). MP isolation protocol from tissues was adapted from Leroyer et 
al.[16]. Briefly, samples were finely cut and centrifuged at 400g, 15 minutes at 4°C followed 
by 12500g, 5 minutes at 4°C to remove cells and cellular debris. Supernatants were 
subsequently centrifuged at 20000g, 45 minutes at 4°C to sediment MPs. MP pellets were 
then resuspended in DMEM (10µL medium/mg tissue). Samples were stored at -80°C until 
MP quantification. 
 
Platelet-free plasma (PFP) preparation 
 Citrate-collected blood was centrifuged at 1500g, 15 minutes at 20°C to remove blood 
cells and then at 13000g, 2 minutes at 20°C to remove platelets. Platelet-free plasma (PFP) 
was immediately frozen in liquid nitrogen and stored at -80°C until MP quantification. 
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MP quantification by flow cytometry 
 MP samples (PFP or MPs isolated from tissues) were incubated with 
fluoroisothiocyanate-conjugated annexin V (BD Biosciences, France) according to the 
manufacturer’s instructions. MP analysis and quantification were performed using calibrated 
10µm-sized beads of known concentration on a FC 500 cytometer (Beckman Coulter, 
France). MP population was determined on a gate of 0.1-1 µm events on a forward light 
scatter and side light scatter dot plot representation, and as positive events on 
fluorescence/forward light scatter plot as previously described [34]. Results are expressed as 
percentage of MP concentration relative to the control group set as 100%. For specific cellular 
origin determination, the following specific antibodies and their specific isotype controls were 
used: CD68 coupled to phycoerythrin (PE) for monocytes and F4/80 coupled to 
phycoerythrin-cyanin 5 (PCy5) for macrophages, CD144-PE for endothelial cells, 
TER119-PE for erythrocytes, CD41-PCy5 for platelets. All antibodies were purchased from 
BD Bioscience (France) and used at 20 ng/mL, except CD68 which was from Beckman 
Coulter (France) and used at 10 ng/mL. 
 
Analysis of atherosclerotic lesions 
 After sacrifice by cervical dislocation, hearts were fixed with 4% phosphate-buffered 
paraformaldehyde (PAF) and 10µm-aortic sinus sections were cut followed by quantitative 
analysis of lipid deposition by Oil red-O staining. Sections were also stained with rat 
monoclonal anti-mouse macrophage MOMA-2 (Santa Cruz Biotechnology, Germany), 
followed by detection with biotinylated secondary antibody and streptavidin-horseradish 
peroxidase. Images were captured using a JVC 3-charge-coupled device video camera and 
analysed using the computer-assisted Quips Image analysis system (Leica Mikroscopic und 
System Gmbh, Germany). 
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Hepatic lipid analysis 
 Frozen liver tissue (50 mg) was homogenized in SET buffer (1 mL ; sucrose 250 mM, 
EDTA 2 mM and Tris 10 mM), followed by two freeze-thaw cycles and three times passing 
through a 27-gauge syringe needle and a final freeze-thaw cycle. Protein content was 
determined using the BCA method (Interchim, France) and TG and cholesterol measured as 
described above. 
 
Histological analysis of the liver 
 At sacrifice, livers were perfused with phosphate buffered saline (PBS) solution via 
the portal vein. After removal of the liver, a part of about 4 mm² was fixed in PAF and 
embedded in paraffin. Five µm paraffin-embedded sections were stained with 
haematoxylin/eosin to evaluate steatosis and inflammation. Seven µm of frozen-liver sections 
were stained with rat monoclonal anti-mouse macrophage MOMA-2 (Santa Cruz 
Biotechnology, Germany), followed by detection with biotinylated secondary antibody and 
streptavidin-horseradish peroxidase, to evaluate macrophage content. Analysis of lipid 
deposition was made by Oil red-O staining on seven µm of frozen-liver sections, using Harris 
haematoxylin for nucleus coloration. 
 
RNA analysis 
 Total RNA was isolated from frozen tissues using the acid guanidium 
thiocyanate/phenol/chloroform method. RNA was reverse-transcribed using Moloney murine 
leukaemia virus-reverse transcriptase and random hexamer primers (Invitrogen, France). 
mRNA levels were quantified by real-time quantitative PCR on a MX-3000 apparatus 
(Agilent, France) using the Brilliant SYBR Green QPCR master mix (Stratagene) and specific 
primers (Table I). Results are expressed normalized to cyclophilin mRNA.  
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Statistical analysis 
The significance of differences (mean  sem) between groups was determined by 
Mann&Whitney test when the analysis was made on 2 groups and ANOVA analysis followed 
by between group post-hoc analysis using the Scheffe test when the analysis was made on 4 
groups. A value of p<0.05 was considered as statistically significant.  
 
Results 
 
MP concentrations are elevated in the aortic sinus and in the liver of apoE2-KI mice 
with atherosclerosis and NASH. 
To induce atherosclerotic lesion development, apoE2-KI mice were fed a Western diet 
for 10 weeks [26]. MP concentrations in the aortic sinus and in PFP were compared to 
apoE2-KI mice fed a chow diet. As expected, compared to mice fed a chow diet, mice fed a 
Western diet displayed an aggravated dyslipidaemia with increased plasma TC and TG levels 
(Sup figure 1), and accelerated lesion development in the aortic sinus (figure 1A). In chow 
diet fed mice, MP concentrations were 699±77 MPs/µL in the aortic sinus and 153±46 
MPs/µL in PFP. Interestingly, MP concentrations in the aortic sinus were significantly higher 
in mice fed a Western diet compared with mice fed a chow diet (figure 1B). By contrast, 
PFP-MP concentrations were similar between the two groups (figure 1C). To better 
characterize the cell origin of the MPs, specific markers were analyzed on MPs isolated from 
atherosclerotic lesions and PFP. As in humans, PFP-MPs mainly originate from platelets and 
erythrocytes. Since macrophages and endothelial cells are the main cells composing 
atherosclerotic lesions of apoE2-KI mice, the concentrations of endothelial- and macrophage-
derived MPs were measured in the atherosclerotic lesions, and platelet-, erythrocyte- and 
monocyte-derived MPs were measured in the PFP of mice fed a Western diet (Sup figure 2). 
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In the atherosclerotic lesions, 18% of MPs were positive for the macrophage marker F4/80 
and 35% positive for the endothelial marker CD144. In PFP, 73% of MPs were positive for 
the erythrocyte marker TER119 and 4% positive for the platelet marker CD41, whereas no 
MP positive for the monocyte marker CD68 was detectable on our conditions. 
To induce NASH, another group of apoE2-KI mice were fed a Western diet for 10 
days [31]. Western diet feeding increased hepatic TG levels (figure 1D) and strongly 
increased in TNF and MCP-1 gene expression in the liver (figure 1E-F). Metalloproteinase-9 
(MMP-9) gene expression showed a tendency to increase (figure 1G). In chow diet fed mice, 
MP concentrations were 8054±2196 MPs/µL in the liver and 96±20 MPs/µL in PFP. Liver 
MP concentration increased in mice fed a Western diet (figure 1H). However, PFP-MP 
concentrations were not significantly different between the mice fed a chow diet and the mice 
fed a Western diet (figure 1I). Macrophage-derived MP concentration in the liver and 
platelet-, erythrocyte- and monocyte-derived MP concentrations in the PFP were measured in 
mice fed a Western diet (Sup figure 2). In the liver of these mice, 3% of MPs were positive 
for the macrophage marker F4/80. In PFP, 88% of MPs were positive for the erythrocyte 
marker TER119 and 12% positive for the platelet marker CD41, whereas no MP positive for 
the monocyte marker CD68 was detectable on our conditions. 
 
Inhibition of atherosclerotic lesion development by fenofibrate is associated with a 
decreased MP concentration in the aortic sinus and PFP. 
 Considering that fenofibrate treatment inhibits atherosclerosis progression in 
apoE2-KI mice, MP levels were determined in mice fed a Western diet supplemented or not 
with fenofibrate (0.04 %) for 10 weeks. Fenofibrate treatment increased expression of the 
PPAR target gene acyl-coA oxidase (ACO) (Sup figure 3A), decreased plasma TC and non-
HDL-C concentrations and increased plasma HDL-C levels (Sup figure 3B). As previously 
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shown [26], fenofibrate treatment inhibited atherosclerosis lesion progression (figures 2A, 
2B), and under these conditions, also significantly reduced MP concentrations in the aortic 
sinus (figure 2C) and in PFP (figure 2D). To determine whether these effects were dependent 
on PPAR, experiments were performed in apoE2-KI mice deficient for PPAR in which 
fenofibrate has no effect on dyslipidemia and atherosclerosis development (our unpublished 
data). Treatment of these mice with fenofibrate did not influence MP concentrations neither in 
the aortic sinus or PFP (figures 2C, 2D).  
 
Short-term fenofibrate treatment decreases MP content in the aortic sinus of mice with 
established atherosclerotic lesions. 
To determine whether PPAR activation exerts its effects on MP concentrations 
independently of changes in plaque size, apoE2-KI mice were fed a Western diet for 8 weeks 
in order to induce atherosclerotic lesion development, and subsequently treated or not with 
fenofibrate (0.2%) for two additional weeks. Fenofibrate treatment increased ACO expression 
(Sup figure 4A), and reduced the Western diet-induced dyslipidaemia as assessed by TC, 
non-HDL cholesterol, TG and HDL-C concentration changes (Sup figure 4B). Under these 
conditions of short-term treatment, fenofibrate did not significantly influence atherosclerosis 
lesion area, nor lipid and macrophage content of the atherosclerotic lesions (figure 3A-C). 
Moreover, gene expression of apoptosis markers, such as B-cell lymphoma-2 (Bcl-2), 
caspase-3 (casp-3) and Bcl-2 associated protein (BAX) was not modified by the treatment. By 
contrast, expression of the inflammatory response genes MCP-1, interleukin-6 (IL-6) and 
TNF was significantly reduced in the aortic sinus of fenofibrate-treated mice (figure 3D). The 
expression of genes involved in efferocytosis, such as thrombospondin-1 (TSP-1), growth 
arrest specific-6 (GAS-6) and c-mer proto-oncogene tyrosine kinase (MERTK) was not 
modified in the aortic sinus upon fenofibrate treatment (figure 3E). 
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Interestingly, fenofibrate reduced MP concentrations in the aortic sinus (figure 3F), 
whereas PFP-MP concentrations were not significantly modified (figure 3G). The 
fenofibrate-induced decrease of MP levels was not observed in apoE2-KI mice deficient for 
PPAR (figure 3F), indicating that the effect is dependent on PPAR. In atherosclerotic 
lesions of fenofibrate-treated wild-type mice, the proportion of endothelial-derived MPs was 
not modified (35.2±0.8% versus 34.5±0.5%, treated group versus control group), whereas the 
proportion of macrophage-derived MPs was significantly reduced (5.6±1.7% versus 
18.4±0.8%, treated group versus control group, p<0.001). 
 
Fenofibrate does not influence liver or PFP-MP concentrations in apoE2-KI mice. 
 To assess the effect of fenofibrate in a model of NASH, apoE2-KI mice were fed a 
Western diet supplemented or not with fenofibrate 0.2% for 10 days [31]. Fenofibrate 
treatment led to the expected effects on hepatic ACO gene expression (Sup figure 5A) and 
improved the Western diet-induced dyslipidaemia (Sup figure 5B). Moreover, fenofibrate 
treatment reduced the hepatic lipid content (figure 4A), and the expression of genes involved 
in inflammatory response (figure 4B) and efferocytosis (figure 4C). Treatment with 
fenofibrate improved steatohepatitis as shown by haematoxylin/eosin, MOMA-2 and Oil Red 
O staining of livers (figure 4D). However, in these conditions, treatment with fenofibrate had 
no effect on MP concentrations neither in the liver (figure 4E) nor in PFP (figure 4F).  
 
Discussion  
Atherosclerosis is characterized by lipid accumulation, chronic inflammation and 
extensive tissue remodelling [35], conditions favourable to trigger MP production by cells of 
the vascular wall, including macrophages, endothelial cells and smooth muscle cells. 
Interestingly, MPs have been detected in atherosclerotic plaques of human carotid arteries 
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[16]. The apoE2-KI mouse fed a Western diet is a model of early atherogenesis [32] in which 
atherosclerotic lesions are mainly composed of foam cells resembling fatty streaks in humans. 
In the present study, we have shown the presence of MPs in a mouse model of atherosclerosis 
and that progression of atherosclerosis in apoE2-KI mice increases MP concentrations in the 
aortic sinus. Steady-state MP concentrations reflect the equilibrium between MP release by 
apoptosis and/or inflammatory stimuli and MP clearance by phagocytic cells. As apoE2-KI 
mice display very low levels of apoptosis in the aortic sinus (unpublished data), MPs in the 
plaques of these mice are likely the result of the inflammation associated with lesion 
development. In addition, since MPs expose phosphatidylserine, an eat-me signal for 
macrophage recognition and phagocytosis [36], MPs could be eliminated by processes similar 
as for apoptotic cells, namely efferocytosis [37, 38]. Thus the increase of MPs in plaques 
could be due to an imbalance between increased production by cells and/or decreased 
elimination by phagocytes.  
Numerous studies reported an association between plasma MP concentrations and 
cardiovascular risk factors [10-15]. Therefore, MPs are potentially interesting biomarkers, 
both as diagnosis and prognostic markers. In our model, plasma MP concentrations did not 
increase during atherosclerosis in apoE2-KI mice. However, plasma MP concentrations in this 
model are very low (in the range of 200-300 MPs/µL) compared to those in atherosclerotic 
patients [16] or in other murine models of atherosclerosis such as low density lipoprotein-
receptor (LDL-R)-deficient mice fed a Western diet for 20 weeks [39]. Moreover, in 
apoE-deficient mice, PFP-MP concentrations are higher in 19 compared to 4 week old-mice 
(363±151 MPs/µL versus 176±50 MPs/µL, our own observations). As apoE-deficient mice 
develop severe atherosclerosis with age associated with a relatively small increase in MP 
concentration, it is possible that the lack of an increase in plasma MP concentrations in 
apoE2-KI mice under Western diet is due to the relatively mild atherosclerosis development.  
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Previous studies have established that fenofibrate treatment reduces atherosclerosis in 
apoE2-KI mice by reducing both lipid content and inflammation in the aorta [26]. In this 
model, the effects of fenofibrate on plasma lipid concentrations are similar to those observed 
in humans, namely TG reduction and HDL-C increase, while PPAR activation has different 
effects in other atherosclerosis models such as apoE-deficient mice or LDL-R-deficient mice 
[28, 40]. Thus, the apoE2-KI mouse is an appropriate pharmacological model to study the 
effects of PPAR activation on dyslipidemia and atherosclerosis. In the present study, 
fenofibrate treatment reduced MP concentrations in the aortic sinus, in association with 
reduced lesion area and inflammation. This effect did not occur in apoE2-KI PPAR-/- mice, 
proving PPAR-dependency. Interestingly, fenofibrate treatment decreased PFP-MP 
concentrations, which possibly reflects the whole body anti-inflammatory effects of 
fenofibrate. Moreover, short-term treatment of apoE2-KI mice with established lesions, in 
which fenofibrate did not reduce atherosclerotic lesion area nor lipid and macrophage content 
in the aortic sinus, resulted in decreased lesion MP concentrations. This suggests that the 
effect of PPAR activation on MP content is independent of its effect on plaque size and 
composition. Short-term treatment with fenofibrate reduced inflammation in the aortic sinus, 
as assessed by decreased expression of genes encoding inflammatory cytokines and 
chemokines, which are known stimuli of MP production. Conversely, since MPs are potent 
inducers of the inflammatory response, reduction of their concentration can contribute to the 
local anti-inflammatory action of fenofibrate. In the aortic sinus, fenofibrate treatment did not 
influence the expression of genes involved in efferocytosis, suggesting that PPAR activation 
has no effect on MP clearance in the aortic sinus. Consequently, PPAR activation could 
inhibit plaque progression by reducing production of MPs, stimuli known to be involved in 
cell recruitment and lesion destabilization.  
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Despite the fact that the mechanisms involved in NASH development are not clearly 
known, it is commonly accepted that it is a progressive process involving steatosis and 
inflammation [41]. It is reasonable to expect that these conditions may result in MP 
generation by liver cells, such as the hepatocytes, Kupffer cells and/or recruited macrophages. 
There are no clinical data available linking MPs with fatty liver diseases. The apoE2-KI 
mouse fed a Western diet for 2 weeks is a model of early NASH, characterized by moderate 
steatosis and inflammation in the liver [31]. In our study, we have shown that NASH 
progression in apoE2-KI mice results in an increase of MPs in the liver, which could in turn 
exacerbate the pathology.  
The diagnosis of NASH is difficult in humans, because the pathology is usually 
asymptomatic and no specific circulating markers have been identified so far. Liver disease is 
determined by high liver transaminase levels in plasma. Imaging techniques are used to 
quantify lipid accumulation, but they do not allow inflammation or fibrosis detection. The 
most informative way to diagnose NASH is by performing a liver biopsy, which allows 
histological analysis and classification according to disease severity. However, this technique 
is invasive, and consequently difficult to perform on all patients. Hence, a link between 
PFP-MP and liver disease could make MPs a valuable marker of NASH, in the same manner 
that MPs are increased in hepatitis [17, 18]. In our study, we did not observe any variation of 
total plasma MP concentrations during NASH development. This can be explained by early 
development of NASH in this model, which may be not sufficient to induce an increase in 
plasma MP concentrations or the fact that PFP-MPs are mainly of erythrocyte origin. Mouse 
models of severe liver disease could provide information whether PFP-MP concentrations 
increase in more advanced pathology. 
Fenofibrate decreases lipid content, steatosis and inflammation in livers of apoE2-KI 
mice fed a Western diet [31], but has no effect neither on hepatic nor on PFP-MP levels. 
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Despite the fact that fenofibrate treatment reduces liver inflammation and macrophage 
number, stimuli responsible for MP production, it also decreases expression of genes involved 
in efferocytosis, potentially leading to impaired clearance of MPs. Indeed, fenofibrate 
treatment could reduce MP production, but also decrease MP clearance, resulting in 
unchanged MP concentrations.  
We furthermore determined the cellular origin of MPs using specific antibodies. 
Surprisingly, we found that the proportion of MPs originating from macrophages is low in 
atherosclerotic lesions and liver (18% and 3% respectively). Atherosclerotic lesions of 
apoE2-KI mice are mainly composed of macrophages and this cell type represents about 10% 
of total cells in the liver. One explanation for the relatively low proportion of 
macrophage-derived MPs may be that cell-specific markers at the surface of macrophages 
could be heterogeneously transferred to MPs. Hence, MPs produced by blebbing from 
macrophages may not express all markers from the cell of origin. For example, only 20% of 
MPs obtained in vitro from the RAW264.7 mouse macrophage cell line after stimulation with 
actinomycin D (0.5µg/mL) for 24 hours express the macrophage markers F4/80 or CD68.  
 
Conclusion  
In conclusion, the apoE2-KI mouse is an appropriate preclinical mouse model to study 
tissue MPs as markers of atherosclerosis and NASH. In this model, PPAR activation 
modulates MP concentrations in atherosclerotic lesions  but not in the liver, identifying this 
model to be appropriate for pharmacological testing using different pharmacological 
approaches.  
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Figure Legends 
 
Figure 1 : Atherosclerosis and NASH progression are associated with increased MP 
concentration in atherosclerotic lesions and in liver but not in PFP of apoE2-KI mice. 
ApoE2-KI mice were fed a chow or Western diet for 10 weeks to induce atherosclerosis 
development (A,B,C) or for 10 days to induce NASH development (D,E,F,G,H,I). 
Atherosclerotic lesion area was quantified by Oil Red O staining (A). Steatohepatitis was 
evaluated measuring liver lipid content (D) and inflammatory gene expression (E,F,G). MPs 
were extracted from aortic sinus (B), liver (H) and platelet-free-plasma (C, I) and quantified. 
Statistically significant differences are indicated (Mann&Whitney test, * p<0.05, ** p<0.01, 
*** p<0.001).  
 
Figure 2 : Fenofibrate decreases atherosclerotic lesion-associated and PFP-MP 
concentrations in a PPAR dependent manner in apoE2-KI mice. 
ApoE2-KI PPAR +/+ and -/- mice were fed for 10 weeks a Western diet supplemented or 
not with fenofibrate (0.04%). Atherosclerotic lesion area was quantified after Oil Red O 
staining (A,B). MPs were extracted from the aortic sinus (C), platelet-free-plasma (D) and 
quantified. 
Statistically significant differences are indicated (A : Mann&Whitney test, * p<0.05; C,D,E : 
ANOVA test, * p<0.05, **  p<0.01).  
CON : Control group, FF : Fenofibrate-treated group 
 
Figure 3 : Short-time PPAR activation decreases MP content in developed 
atherosclerotic lesions, but has no effect on PFP-MP concentrations in apoE2-KI mice. 
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ApoE2-KI PPAR +/+ and -/- were fed for 8 weeks a Western diet alone and then with a 
Western diet supplemented or not with fenofibrate (0.2%) for 2 additional weeks. 
Atherosclerotic lesion area (A) and lipid content (B) were quantified after Oil Red O staining. 
Macrophage content was measured by MOMA-2 staining (C). Expression of genes involved 
in inflammation, apoptosis (D) and efferocytosis (E) was measured in the aortic sinus. MPs 
were extracted from the aortic sinus (F) and platelet-free-plasma (G) and quantified. 
Statistically significant differences are indicated (ANOVA test, * p<0.05, **  p<0.01, *** 
p<0.001).  
CON : Control group, FF : Fenofibrate-treated group 
Figure 4 : Fenofibrate treatment does not influence MP concentration in liver and in 
PFP of apoE2-KI mice. 
ApoE2-KI mice were fed for 10 days with Western diet supplemented or not with fenofibrate 
(0.2%). Hepatic steatosis was evaluated by measuring lipid content (A), inflammatory gene 
expression (B), haematoxylin/eosin (H&E), MOMA-2 and Oil Red O staining (D). 
Expression of genes involved in efferocytosis was measured in the liver (C). MPs were 
extracted from liver (E) and platelet-free-plasma (F) and quantified. 
Statistically significant differences are indicated (Mann&Whitney test, * p<0.05, ** p<0.01, 
*** p<0.001)  
CON : Control group, FF : Fenofibrate-treated group  
  
